A cost-effective, high sensitivity 10-color single tube flow-cytometry (FC) based B-cell precursor acute lymphoblastic leukemia (BCPALL) minimal residual disease (MRD) assay

A cost-effective, high sensitivity 10-color single tube flow-cytometry (FC) based B-cell precursor acute lymphoblastic leukemia (BCPALL) minimal residual disease (MRD) assay

Bibliographic Details
Main Authors:	Dilshad Dhaliwal, Gaurav Chatterjee, Sitaram Ghogale, Nilesh Deshpande, Y. Badrinath, Sumeet Gujral, P.G. Subramanian, Shripad Banawali, Gaurav Narula, Brijesh Aurora, Prashant Tembhare
Format:	Article
Language:	English
Published:	Elsevier 2016-01-01
Series:	Pediatric Hematology Oncology Journal
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468124516300894

Similar Items

Expression pattern of CD179 in b-cell acute lymphoblastic leukemia (B-All): A potential utility for lineage assignment and B-ALL MRD monitoring
by: Tembhare Prashant, et al.
Published: (2022-01-01)

Standardization of 13-color high-sensitivity measurable residual disease (MRD) assessment in B-cell lymphoblastic leukemia (B-ALL) treated with novel anti-CD19 immunotherapies
by: Prashant Tembhare, et al.
Published: (2022-01-01)

Post-induction Measurable Residual Disease Using Multicolor Flow Cytometry Is Strongly Predictive of Inferior Clinical Outcome in the Real-Life Management of Childhood T-Cell Acute Lymphoblastic Leukemia: A Study of 256 Patients
by: Prashant R. Tembhare, et al.
Published: (2020-04-01)

P360: MEASURABLE/MINIMAL RESIDUAL DISEASE (MRD) STATUS IS THE MOST RELEVANT INDICATOR OF CLINICAL OUTCOME IN MIXED PHENOTYPIC ACUTE LEUKEMIAS (MPAL)
by: Prashant Tembhare, et al.
Published: (2023-08-01)

PB1949: ROLE OF LAIR1 (CD305) IN FLOW CYTOMETRIC DETECTION OF OCCULT BONE MARROW INVOLVEMENT IN NON-CLL B-CELL NON-HODGKIN LYMPHOMA
by: Sitaram Ghogale, et al.
Published: (2023-08-01)

Clinical profile and outcome of early T-precursor (ETP) acute lymphoblastic leukemia (ALL) in a tertiary care cancer centre
by: Cheriyalinkal Parambil Badira, et al.
Published: (2016-01-01)

Report of proceedings of the national meeting on "Guidelines for Immunophenotyping of Hematolymphoid Neoplasms by Flow Cytometry"
by: Gujral Sumeet, et al.
Published: (2008-04-01)

Hypergranular precursor B-cell acute lymphoblastic leukemia in a 16-year-old boy
by: Tembhare Prashant, et al.
Published: (2009-07-01)

Anaplastic lymphoma kinase-positive large B-cell lymphoma: Unusual clinical and immunophenotypic features
by: Komal S Galani, et al.
Published: (2014-01-01)

Utility of flow cytometry screening before MRD testing in multiple myeloma
by: Vandana Panakkal, et al.
Published: (2023-04-01)

Transient abnormal myelopoiesis: A case series and review of the literature
by: Vandana Baloda, et al.
Published: (2017-03-01)

MRD Monitoring by Multiparametric Flow Cytometry in AML: Is It Time to Incorporate Immune Parameters?
by: Ilias Pessach, et al.
Published: (2022-09-01)

'Childhood systemic mastocytosis associated with t (8; 21) (q22; q22) acute myeloid leukemia'
by: Nikhil Rabade, et al.
Published: (2016-01-01)

Pediatric plasmablastic lymphoma – Ten years experience in a tertiary care centre in India
by: Nirmalya Pradhan, et al.
Published: (2016-01-01)

Exflagellated microgametes of <i> Plasmodium vivax</i> in human peripheral blood: A case report and review of the literature
by: Tembhare Prashant, et al.
Published: (2009-04-01)

Multiparametric Flow Cytometry for MRD Monitoring in Hematologic Malignancies: Clinical Applications and New Challenges
by: Giovanni Riva, et al.
Published: (2021-09-01)

Hepatic mass: A rare presentation of childhood hepatic Burkitt lymphoma
by: Sneha Tandon, et al.
Published: (2020-06-01)

Treatment and long-term follow-up of children with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): Experience from the Tata Memorial Hospital pediatric CML cohort over 2 decades
by: Nirmalya Roy Moulik, et al.
Published: (2022-01-01)

Leukemic phase of anaplastic lymphoma kinase positive, anaplastic large cell lymphoma
by: Vijaya S Gadage, et al.
Published: (2011-01-01)

Morphological spectrum of leukemic mantle cell lymphoma
by: Khaliqur Rahman, et al.
Published: (2012-01-01)

Applicability of 2008 World Health Organization classification system of hematolymphoid neoplasms: Learning experiences
by: Sushil Modkharkar, et al.
Published: (2018-01-01)

Utility of Immunophenotypic Measurable Residual Disease in Adult Acute Myeloid Leukemia—Real-World Context
by: Nikhil Patkar, et al.
Published: (2019-06-01)

Measurable Residual Disease (MRD) by Flow Cytometry in Adult B-Acute Lymphoblastic Leukaemia (B-ALL) and Acute Myeloid Leukaemia (AML): Correlation with Molecular MRD Testing and Clinical Outcome at One Year
by: Riana van der Linde, et al.
Published: (2023-10-01)

Voriconazole plasma levels, its determinants, and impact on outcome of invasive fungal infections in children with cancer: a prospective study
by: Vasudeva Bhat, et al.
Published: (2016-01-01)

PB1980: MULTIPLE MYELOMA: ADOPTING MRD BY NEXT GENERATION FLOW CYTOMETRY (NGF) AND FUNCTIONAL IMAGING GUIDED CONSOLIDATION INTO CLINICAL ROUTINE
by: D. Boeckle, et al.
Published: (2022-06-01)

HOW TO INCORPORATE MRD IN CLINICAL TRIALS
by: Jesus San-Miguel
Published: (2022-04-01)

MRD in AML: The Role of New Techniques
by: Maria Teresa Voso, et al.
Published: (2019-07-01)

Changes in MRD's Team of Editors-in-Chief
by: Susanne Wymann von Dach, et al.
Published: (2021-08-01)

Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party
by: Jesse M. Tettero, et al.
Published: (2022-01-01)

Mechanism of Fcγ receptor-mediated trogocytosis-based false-positive results in flow cytometry.
by: Sakiko Masuda, et al.
Published: (2012-01-01)

PB1771: THE SIGNIFICANCE OF MRD DETECTION BY FLOW CYTOMETRY IN TRACING R/R B-ALL PATIENTS RECEIVING CD-19-CART BRIDGING TO ALLO-HSCT
by: M. chen, et al.
Published: (2022-06-01)

MRD IN BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM
by: Aleksandra Palladina, et al.
Published: (2022-10-01)

Study on the Effect Mechanism of MRD to Rotor System
by: Jun Wang, et al.
Published: (2019-05-01)

Correction Notice: Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party
Published: (2022-03-01)

Outcome of pediatric relapsed refractory Hodgkin lymphoma experience from Tata Memorial Hospital , Mumbai
by: Ankita Pandey, et al.
Published: (2022-01-01)

MRD negativity: considerations for older adults with multiple myeloma
by: Hira Mian, et al.
Published: (2023-11-01)

ACUTE MEGACARYOBLASTIC LEUKEMIA IN CHILDREN: DIAGNOSTICS AND MRD MONITORING
by: Aleksandra Palladina, et al.
Published: (2021-11-01)

SERS-Based Assessment of MRD in Acute Promyelocytic Leukemia?
by: Cristina Turcas, et al.
Published: (2020-06-01)

Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India
by: Nikhil Rabade, et al.
Published: (2018-01-01)

P889: WILL OUTCOME IMPROVE BY TREATING MULTIPLE MYELOMA PATIENTS AT MRD RELAPSE? THE REMNANT STUDY (RELAPSE FROM MRD NEGATIVITY AS INDICATION FOR TREATMENT)
by: F. B. Askeland, et al.
Published: (2022-06-01)